Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

• Maria Winqvist,
• Per-Ola Andersson,
• Anna Asklid,
• Karin Karlsson,
• Claes Karlsson,
• Birgitta Lauri,
• Jeanette Lundin,
• Mattias Mattsson,
• Stefan Norin,
• Anna Sandstedt,
• Richard Rosenquist,
• Florentin Späth,
• Lotta Hansson,
• Anders Österborg,
• for the Swedish CLL Group

Affiliations

Maria Winqvist

Department of Hematology, Karolinska University Hospital, Stockholm;Department of Oncology-Pathology, Karolinska Institutet, Stockholm

Per-Ola Andersson

Department of Hematology, Borås Hospital

Anna Asklid

Department of Oncology-Pathology, Karolinska Institutet, Stockholm

Karin Karlsson

Department of Hematology, Lund University Hospital

Claes Karlsson

Department of Hematology, Karolinska University Hospital, Stockholm;Department of Oncology-Pathology, Karolinska Institutet, Stockholm

Birgitta Lauri

Department of Hematology, Sunderby Hospital, Sunderbyn-Luleå

Jeanette Lundin

Department of Hematology, Karolinska University Hospital, Stockholm;Department of Oncology-Pathology, Karolinska Institutet, Stockholm

Mattias Mattsson

Department of Hematology, Uppsala University Hospital

Stefan Norin

Department of Internal Medicine, Karolinska Institutet, Stockholm

Anna Sandstedt

Department of Hematology, Linköping University Hospital

Richard Rosenquist

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm

Florentin Späth

Department of Radiation Sciences, Oncology, Umeå University, Sweden

Lotta Hansson

Department of Hematology, Karolinska University Hospital, Stockholm;Department of Oncology-Pathology, Karolinska Institutet, Stockholm

Anders Österborg

Department of Hematology, Karolinska University Hospital, Stockholm;Department of Oncology-Pathology, Karolinska Institutet, Stockholm

for the Swedish CLL Group